Skip to content
10-Q

Quarterly Report

CEREVEL THERAPEUTICS HOLDINGS, INC.

0000950170-23-017180

← back to feed
Filed
May 3, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Apr 28, 2023 156.83M sh
Long Term Debt Q1 2023 · Mar 31, 2023 $383.81M
Current Liabilities Q1 2023 · Mar 31, 2023 $62.96M
Current Liabilities Q1 2023 · Dec 31, 2022 $72.56M
Total Liabilities Q1 2023 · Mar 31, 2023 $498.64M
Total Liabilities Q1 2023 · Dec 31, 2022 $496.58M
Current Assets Q1 2023 · Mar 31, 2023 $840.78M
Current Assets Q1 2023 · Dec 31, 2022 $905.65M
Total Assets Q1 2023 · Mar 31, 2023 $930.35M
Total Assets Q1 2023 · Dec 31, 2022 $1.02B
Cash And Equivalents Q1 2023 · Dec 31, 2022 $136.52M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $91.76M
Shares Diluted Q1 2023 · Mar 31, 2022 147.98M sh
Capex Q1 2023 · Mar 31, 2022 $2.2M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$67.65M
Stockholders Equity Q1 2023 · Mar 31, 2022 $521.5M
Stockholders Equity Q1 2023 · Dec 31, 2021 $578.73M
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.46
Eps Basic Q1 2023 · Mar 31, 2022 −$0.46
Sga Expense Q1 2023 · Mar 31, 2022 $17.51M
Rd Expense Q1 2023 · Mar 31, 2022 $55.02M
Net Income Q1 2023 · Mar 31, 2022 −$68.29M
Operating Income Q1 2023 · Mar 31, 2022 −$72.53M